Clinical Trials Logo

Myofascial Pain Syndromes clinical trials

View clinical trials related to Myofascial Pain Syndromes.

Filter by:

NCT ID: NCT01280747 Terminated - Fibromyalgia Clinical Trials

Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

Start date: January 2011
Phase:
Study type: Observational

The investigators hypothesize that fibromyalgia (FM) and painful diabetic peripheral neuropathy (pDPN) patients with access restrictions on pregabalin will lead to higher healthcare resource use and cost compared to patients without such restrictions on pregabalin in a naturalistic setting. The randomization will occur at the physician level and not the patient level.

NCT ID: NCT01261650 Terminated - Fibromyalgia Clinical Trials

Influence of Transcranial Direct Current Stimulation of the Primary Motor Cortex on Pain Sensation in Patients Suffering From Fibromyalgia Syndrome

Start date: December 2010
Phase: Phase 4
Study type: Interventional

Fibromyalgia is a common chronic pain syndrome characterized by bad treatable chronic widespread pain present at a similar level for at least 3 months. The aim of this study is to examine if 3 weeks of transcranial direct current stimulation is a suitable therapy to reduce chronic pain.

NCT ID: NCT01219049 Terminated - Fibromyalgia Clinical Trials

L-Tyrosine Supplementation in Patients With Fibromyalgia

Start date: January 2010
Phase: N/A
Study type: Interventional

Patients in the study, who have a diagnosis of fibromyalgia, will be randomly assigned to take the amino acid L-tyrosine or placebo (blank pill) for 3 weeks. They will fill out questionnaires about their symptoms and see if they have any improvement. The investigators hypothesis is that taking tyrosine will help alleviate the symptoms of fibromyalgia.

NCT ID: NCT01087593 Terminated - Fibromyalgia Clinical Trials

Estrogens Effect on Pain in Postmenopausal Women Suffering of Fibromyalgia

Start date: August 2001
Phase: N/A
Study type: Interventional

In order to evaluate the potential effects of estrogen treatment in postmenopausal women with fibromyalgia, the investigators used quantitative sensory tests before and after eight weeks of estrogen treatment as compared with placebo treatment.

NCT ID: NCT01041495 Terminated - Pain Clinical Trials

Cyclobenzaprine Extended Release (ER) for Fibromyalgia

Start date: June 2009
Phase: Phase 4
Study type: Interventional

Amrix (Cyclobenzaprine hydrochloride Extended release capsules) is approved by the FDA as a muscle relaxant, indicated for the treatment of muscle spasm associated with acute, painful musculoskeletal conditions. Cyclobenzaprine ER (Amrix TM) has a distinct pharmacokinetic profile providing early systemic exposure and consistent plasma concentration over several hours. Overall, a single dose of Amrix 30 mg is similar to that of cyclobenzaprine immediate release 10 mg three times daily. This ER formula should improve compliance, with similar efficacy and possibly less side effects as is often the case with slower release formulations. There are clinical studies showing that cyclobenzaprine can alleviate pain secondary to Fibromyalgia induced muscle tone. This multi-layered evidence base suggests that cyclobenzaprine may be able to alleviate pain in fibromyalgia. Theoretically in fibromyalgia, pain is interpreted centrally and possibly occurs due to said muscle spasm . Cyclobenzaprine may relieve this pain, thus allowing patients to function better during the day and sleep better at night. Cyclobenzaprine has tricyclic antidepressant structure which may also allow pain signal dampening in the spinal cord as well, similar to amitriptyline which is used off-label for neuropathic pain as well. Fibromyalgia (FM) is an illness that may involve medical, rheumatologic, autoimmune, sleep, endocrine and psychiatric pathology. It is a syndrome of recurrent pain at trigger points. Greater than 90% of these patients will report fatigue as a key symptom as well. There are several investigation lines into the treatment of FM induced pain. Exercise, behavioral therapy, amitryptiline, duloxetine, tramadol, sodium oxybate, pregabalin all have randomized trials and almost all focus on pain. There are very few studies evaluating cyclobenzaprine and none studying to Cyclobenzaprine ER formulation. None evaluate pain reduction, sleep and fatigue improvement. Cyclobenzaprine is a drug with minimal adverse effects (dry mouth, dizziness, fatigue, constipation, somnolence, nausea, and dyspepsia). It may have a safer tolerability profile than some of the FM medications noted above. As cyclobenzaprine is often studied and often added as an augmentation agent to patients' regimens who suffer from acute painful musculoskeletal conditions, the authors feel that cyclobenzaprine would also be effective in this population. The authors wish to conduct a study to determine if cyclobenzaprine ER is safe and tolerable in the treatment of FM induced pain, and secondary fatigue and insomnia. This initial study may allow for continued regulatory studies with this product in FM subjects. The authors propose a double-blind placebo controlled study to determine if cyclobenzaprine ER is safe and effective in reversing FM induced pain, and secondary fatigue and insomnia.

NCT ID: NCT00876317 Terminated - Clinical trials for Tenosynovitis and Bursitis Affecting the Shoulder

Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety two oral doses of etoricoxib (60 mg and 90 mg) daily in acute soft tissue rheumatism affecting the shoulder.

NCT ID: NCT00793520 Terminated - Fibromyalgia Clinical Trials

Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia

Start date: November 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of milnacipran on how the brain processes pain in patients with fibromyalgia and to assess the relationship between this effect and brain activation patterns during functional magnetic resonance imaging.

NCT ID: NCT00754221 Terminated - Fibromyalgia Clinical Trials

Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

Start date: May 2008
Phase: Phase 3
Study type: Interventional

This is a study to investigate the long-term safety and effectiveness [S,S]-Reboxetine in relieving the symptoms of Fibromyalgia in patients.

NCT ID: NCT00696787 Terminated - Fibromyalgia Clinical Trials

A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate if DVS SR is safe and effective in the treatment of pain associated with fibromyalgia syndrome, and if so to identify the efficacious doses.

NCT ID: NCT00689052 Terminated - Fibromyalgia Clinical Trials

Pramipexole ER vs. Placebo in Fibromyalgia

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the efficacy and safety of an extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment of fibromyalgia. The objective of the open-label phase is to assess the safety profile and effect of Pramipexole (PPX) extended-release (ER) in fibromyalgia patients over a 24-week period.